explore -WSS

explore

author：leisure time 2025-08-08 05:32:58 - browse：69

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： FDA approves first new drug developed for postpartum depression

WSS

Biden administration plans revamp of organ transplant system

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Biden administration plans revamp of organ transplant system

Reanimated hearts work just as well for transplants, study finds

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Sea level rise could wash away turtle breeding grounds around the world, researchers say

knowledge

explore

knowledge

Continuity nursing helped my family in our darkest PICU moments

My superpower is killing ticks

In Memoriam: Notable people who died in 2023

Attacks on the drug industry will lead to fewer breakthroughs

State Dept. review finds Biden bears some blame for Afghanistan failures

Attacks on the drug industry will lead to fewer breakthroughs

Apple is now the first public company to be valued at $3 trillion

What the cancer research community can learn from the Covid response

New air purifier tech could be key to improving indoor air quality

A public health expert passes on football's full body collisions for youths

focus

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Attacks on the drug industry will lead to fewer breakthroughs

Senate panel passes drug pricing bills, but drops one PBM reform

Nearly two

Biden administration plans revamp of organ transplant system

FDA approves first new drug developed for postpartum depression

explore

knowledge

leisure time

entertainment